Close Menu

NEW YORK – Clinical genetics firm Blueprint Genetics and rare disease diagnostics company Archimedlife Medical Laboratory said today that they have partnered to offer biochemical testing for rare diseases in North America.

Under the agreement, Blueprint Genetics is licensing Archimedlife's technology and tests to offer biochemical testing at its Seattle laboratory, which also provides next-gen sequencing-based genetic testing. The combined testing services will be available in early 2020.

Financial terms and other details of the partnership were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
19
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.